...
首页> 外文期刊>Methods: A Companion to Methods in Enzymology >Bispecific anti-mPDGFR beta x cotinine scFv-C-kappa-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFR beta expressing cells
【24h】

Bispecific anti-mPDGFR beta x cotinine scFv-C-kappa-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFR beta expressing cells

机译:双特异性抗MPDGFRβX Cotinine ScFv-C-Kappa-SCFV融合蛋白和Cotinine-Duocarmycin可以形成抗体 - 药物缀合物样络合物,其施加对MPDGFRβ表达细胞的细胞毒性

获取原文
获取原文并翻译 | 示例
           

摘要

Antibody selection for antibody-drug conjugates (ADCs) has traditionally depended on its internalization into the target cell, although ADC efficacy also relies on recycling of the receptor-ADC complex, endo-lysosomal trafficking, and subsequent linker/antibody proteolysis. In this study, we observed that a bispecific anti-murine platelet-derived growth factor receptor beta (mPDGFR beta) x cotinine single-chain variable fragment (scFv)-kappa constant region (C-kappa)-scFv fusion protein and cotinine-duocarmycin can form an ADC-like complex to induce cytotoxicity against rnPDGFR beta expressing cells. Multiple anti-mPDGFR beta antibody candidates can be produced in this bispecific scFv-C-kappa-scFv fusion protein format and tested for their ability to deliver cotinine-conjugated cytotoxic drugs, thus providing an improved approach for antibody selection in ADC development.
机译:抗体 - 药物缀合物(ADC)的抗体选择传统上依赖于其内化进入靶细胞,尽管ADC疗效也依赖于受体-ADC复合物,内寡溶酶体运输和随后的接头/抗体蛋白水解的再循环。 在这项研究中,我们观察到一种双特异性抗鼠血小板衍生的生长因子受体β(MPDGFRβ)X Cotinine单链可变片段(SCFV)-Kappa恒定区(C-Kappa)-SCFV融合蛋白和Cotinine-Duocarmycin 可以形成adc样复合物,以诱导对表达细胞的rnpdgfrβ的细胞毒性。 多种抗MPDGFRβ抗体候选物可以以这种双特异性SCFV-C-Kappa-SCFV融合蛋白格式生产并测试其能够提供胞苷缀合的细胞毒性药物,从而提供了ADC发育中抗体选择的改进方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号